John Alexander Kelly

John Alexander Kelly (finance chief) discloses dealings in Precision Biosciences Inc to SEC (Form 4). Over a trading history stretching from 31 August 2021 to 17 February 2026, the count stands at 25 filings.

Market trades split into 7 purchases (€230k) and 1 sale (€54k). The net balance comes to €176k on the buying side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 6 share grants and 11 option exercises.

A typical purchase (the median) is worth €40k. Clusters matter here: 1 out of 6 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

On 19 February 2026 came the latest disclosure, an option exercise in Precision Biosciences Inc. The most recent open-market purchase was published on 31 December 2024, 656 days ago. Typically, a trade is published a median of 4 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.